Featured Event! Spotlight Theater Presentation

Advancements in new immuno-oncology therapeutics have necessitated comprehensive cell humanized mouse platforms that better support engraftment of human immune cell types such as T cells, B cells, myeloid cells, natural killer cells, and gamma delta T cells. Hematopoietic stem cell (HSC) and peripheral blood mononuclear cell (PBMC)-engrafted mouse models are distinct modalities that enable in vivo study of therapies that engage both human immune cells and human oncology-relevant targets. Immune cell and tumor humanized platforms enable evaluation of the preclinical efficacy and safety of new immuno-oncology therapeutics, leading to improved design and outcomes of clinical trials.

Join us in person for this special presentation to learn from scientists who will present their research findings using these models, with a preview of JAX new model, hu-NSG-SGM3-IL15-MHC I/II DKO, a comprehensive cell humanized PBMC mouse platform for Immuno-Oncology discovery.

This in person Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater are the opinions of the presenter and do not represent the position or the opinion of the American Association for Cancer Research® (AACR) or its members.

2026 HuPK Preclinical Services Award

The Jackson Laboratory is excited to announce an opportunity for you to leverage our innovative HuPK™ (humanized FcRn) platform as part of your antibody-based therapeutic pipeline! We invite you to submit an entry form to be considered as a recipient of the JAX 2026 HuPK Preclinical Services Award of $15,000 USD applied toward a new HuPK Services project this year! Simply share with us a brief abstract describing your proposed project using the HuPK platform in your research study in order to be considered!